Clinical trials: Embryonal Neoplasm
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
- Trial name
- NCT04762602
- Testing
- HMPL-306
- Where
- 11 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.
- Trial name
- Neo Trio (NCT02858921)
- Testing
- Dabrafenib, Trametinib, Pembrolizumab
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Melanoma Institute Australia
Advanced Melanoma, Metastatic Melanoma
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable).
- Conditions
- Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01134614
- Testing
- Ipilimumab, Sargramostim
- Where
- 257 sites in United States
- Volunteers
- 245 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- Spencer (NCT04187404)
- Testing
- EO2401, Nivolumab
- Where
- 12 sites in United States, Denmark and 6 more
- Volunteers
- 70 people
- Sponsor
- Enterome
Adult Brain Glioblastoma, Glioblastoma Multiforme
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
- Trial name
- NCT02078648
- Testing
- SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- Stemline Therapeutics, Inc.
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma
- Trial name
- NCT01055314
- Testing
- Cixutumumab, Cyclophosphamide, Dactinomycin
- Where
- 139 sites in United States, Australia and 2 more
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Neuroectodermal Tumors, Rhabdomyosarcoma
Trial of Afatinib in Pediatric Tumours
Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort/Phase II part. The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2.
- Trial name
- NCT02372006
- Testing
- afatinib
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Boehringer Ingelheim
Glioma, Malignant Glioma
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor is clinically…
- Conditions
- Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma
- Trial name
- NCT02924038
- Testing
- IMA950, poly-ICLC, Varlilumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nicholas Butowski
High Risk Neuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT03794349
- Testing
- Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride
- Where
- 145 sites in United States, Australia and 3 more
- Volunteers
- 94 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure. The first phase of the study (dose escalation) will determine the maximum tolerated dose (MTD).
- Trial name
- NCT02296476
- Testing
- Birabresib
- Volunteers
- 12 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
- Trial name
- NCT00948389
- Testing
- Dasatinib, Lomustine
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Bristol-Myers Squibb
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- ACTIVATe (NCT00643097)
- Testing
- PEP-3 vaccine, sargramostim, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- John Sampson
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Carcinoid Tumor, Carcinoid Tumor of GI System
Cabozantinib and Nivolumab for Carcinoid Tumors
This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the…
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Trial name
- NCT04197310
- Testing
- Nivolumab, Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Oligodendroglioma, Oligoastrocytoma
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
This multicenter, open-label, phase II trial aims to assess the safety and efficacy of palbociclib in adult patients with Oligodendroglioma or recurrent oligoastrocytoma anaplastic with the activity of the protein RB preserved.
- Trial name
- NCT02530320
- Testing
- Palbociclib
- Where
- 11 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Melanoma
Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
The purpose of this study is to understand how people make decisions about sun protection. This study is important in helping to protect against sun exposure, since it is a main risk factor for melanoma.
- Trial name
- NCT01004952
- Testing
- screening questionnaire
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Uveal Melanoma
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
This phase II trial studies the effect of combining defactinib and VS-6766 in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT04720417
- Testing
- Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.